Myostatin
Also known as: GDF-8, Growth Differentiation Factor 8
Myostatin (GDF-8) is a naturally occurring myokine that negatively regulates skeletal muscle growth and development. Research focuses on myostatin inhibition as a therapeutic strategy for muscle wasting diseases, sarcopenia, and age-related muscle loss. Direct myostatin administration is not clinically used; research emphasizes inhibitors and antagonists.
Research Status
Myostatin inhibitors are in active clinical development for muscle wasting diseases, sarcopenia, and muscular dystrophies. Multiple monoclonal antibodies and soluble receptor constructs have entered Phase II/III trials. Direct myostatin peptide administration is not used clinically; research focuses on antagonists and inhibitors.
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Typically resolve within 24–48 hours. Rotate injection sites to minimize recurrence. Apply ice if swelling persists. Use a new needle for each injection and ensure proper sterile technique.
Usually mild and brief. Allow the solution to reach room temperature before injection. Ensure the needle is sharp and properly inserted. Slow injection (3–5 seconds) reduces discomfort.
Develops with repeated injections in the same site. Prevent by rotating injection sites systematically. Maintain at least 1 inch between injection points. If lipodystrophy develops, avoid that area for 2–3 months.
May occur in the first few days of use. Usually self-resolving. Stay well hydrated and take over-the-counter analgesics if needed.
Typically transient. Take the injection with food if tolerated. Discontinue if severe or persistent.
May occur during the first 1–2 weeks as the body adapts. Usually resolves spontaneously. Ensure adequate sleep and hydration.
May reflect increased muscle protein synthesis and adaptation. Typically mild and self-limiting. Ensure adequate recovery and hydration.
Seek immediate medical attention if severe. Mild rash may respond to antihistamines. Discontinue use if allergic symptoms develop. Do not re-inject if prior allergic reaction occurred.
Medical emergency. Seek immediate emergency care. Have epinephrine available if you have a history of severe allergies. Discontinue use permanently if anaphylaxis occurs.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | - |
| Frequency | |
| Route | Intravenous (IV) — for monoclonal antibody inhibitors, Subcutaneous (SC) — for some peptide antagonists and receptor constructs, Intramuscular (IM) — for certain research formulations |
Myostatin is not administered directly as a therapeutic. Research focuses on myostatin INHIBITORS (monoclonal antibodies, soluble ActR2B receptors, antagonistic peptides). Dosing varies by inhibitor type and formulation. This entry is for educational reference on myostatin biology and inhibition strategies.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 26000 |
Myostatin is a TGF-β superfamily member that acts as a negative regulator of muscle mass by binding to activin type II receptors (ActR2B) on muscle cells, suppressing myogenic differentiation and protein synthesis. Inhibition of myostatin signaling removes this brake on muscle growth, allowing increased muscle protein synthesis and hypertrophy. Research explores myostatin inhibitors (monoclonal antibodies, soluble receptors, and antagonistic peptides) rather than myostatin itself as therapeutic agents.
ActR2B/Smad2/3 Signaling
Myostatin binds activin type II B receptors, activating Smad2/3 transcription factors that suppress myogenic gene expression and protein synthesis. Inhibition of this pathway promotes muscle growth and prevents atrophy.
Myogenic Differentiation
Myostatin suppresses myogenic regulatory factors (MyoD, myogenin) that drive muscle cell differentiation. Blocking myostatin allows these factors to promote myoblast fusion and myotube formation.
Protein Synthesis vs. Degradation
Myostatin inhibition shifts the balance toward increased mTOR-mediated protein synthesis and reduced ubiquitin-proteasome-mediated protein degradation in muscle tissue.
- Myostatin is a secreted signaling protein, not typically administered as a therapeutic peptide itself
- Myostatin inhibitors (antibodies, soluble receptors, antagonistic peptides) are the focus of clinical and research development
- Myostatin knockout or inhibition in animal models produces dramatic increases in muscle mass without exercise
- Myostatin levels increase with age and in muscle wasting conditions; inhibition may reverse age-related sarcopenia
- ActR2B is the primary receptor for myostatin; ligand traps and receptor antagonists are primary inhibition strategies
Track your Myostatin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Myostatin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.